Cambium Bio (ASX:CMB) Net Income From Continuing Operations: A$-3.57 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CMB Cambium Bio Ltd ASX:CMB
26 GF Score
Price A$0.42
! 4 Warning Signs
View Full Analysis

What is Cambium Bio Net Income From Continuing Operations?

Cambium Bio ASX:CMB 26 Net Income From Continuing Operations is A$-3.57 Mil as of Dec. 2025. GuruFocus rates ASX:CMB with a GF Score™ of 26/100. The stock has 4 warning signs investors should review.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Cambium Bio's net income from continuing operations for the six months ended in Dec. 2025 was A$-1.46 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-3.57 Mil.

Cambium Bio Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for Cambium Bio's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cambium Bio Net Income From Continuing Operations Chart

Cambium Bio Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.15 -4.31 -3.38 -2.26 -3.84

Cambium Bio Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.12 -1.14 -1.73 -2.12 -1.46
ASX:CMB
26GF Score
Cambium Bio Ltd ASX:CMB
Net Income From Continuing Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cambium Bio Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-3.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of A$-3.57 Mil mean?
Cambium Bio (ASX:CMB) has a Net Income From Continuing Operations of A$-3.57 Mil as of Dec. 2025. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Cambium Bio and its competitors.
Is Cambium Bio's Net Income From Continuing Operations too high?
Cambium Bio's current Net Income From Continuing Operations is A$-3.57 Mil. Overall, Cambium Bio has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's Net Income From Continuing Operations compare to VRTX and REGN?
Cambium Bio's Net Income From Continuing Operations of A$-3.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Biotechnology company?
A good Net Income From Continuing Operations depends on the Biotechnology industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Cambium Bio and its competitors. Cambium Bio's current Net Income From Continuing Operations is A$-3.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current Net Income From Continuing Operations of A$-3.57 Mil. The current Net Income From Continuing Operations is A$-3.57 Mil. Cambium Bio's overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current Net Income From Continuing Operations is A$-3.57 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambium Bio Business Description

Address Unit 2.06, 31 Lexington Drive, Bella Vista, NSW, AUS, 2153
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
26GF Score

Get the complete analysis for ASX:CMB

Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.42
Price